{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Hormone+Receptor+Positive+Breast+Cancer&page=10",
    "query": {
      "condition": "Metastatic Hormone Receptor Positive Breast Cancer",
      "page": 10
    },
    "page_size": 10
  },
  "pagination": {
    "page": 10,
    "page_size": 10,
    "total_count": 233,
    "total_pages": 24,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Hormone+Receptor+Positive+Breast+Cancer&page=11&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Hormone+Receptor+Positive+Breast+Cancer&page=9&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-15T02:19:02.041Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01857193",
      "title": "Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "ribociclib (LEE011)",
          "type": "DRUG"
        },
        {
          "name": "Exemestane",
          "type": "DRUG"
        },
        {
          "name": "Everolimus (RAD001)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 132,
      "start_date": "2013-09-06",
      "completion_date": "2020-04-16",
      "has_results": false,
      "last_update_posted_date": "2021-04-13",
      "last_synced_at": "2026-10-15T02:19:02.041Z",
      "location_count": 8,
      "location_summary": "Fayetteville, Arkansas • Miami, Florida • Boston, Massachusetts + 5 more",
      "locations": [
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01857193"
    },
    {
      "nct_id": "NCT06878248",
      "title": "A Study to Assess CLBR001+ABBV-461 in Subjects With Locally Advanced or Metastatic Breast Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Breast Cancer Metastatic",
        "Locally Advanced Breast Cancer (LABC)",
        "Malignant Neoplasm of Breast",
        "Triple Negative Breast Cancer (TNBC)",
        "Hormone Receptor-Positive Breast Cancer",
        "HER2 + Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Two Component Product CLBR001 + ABBV-461",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Calibr, a division of Scripps Research",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2025-04-17",
      "completion_date": "2026-04-09",
      "has_results": false,
      "last_update_posted_date": "2026-05-28",
      "last_synced_at": "2026-10-15T02:19:02.041Z",
      "location_count": 5,
      "location_summary": "Augusta, Georgia • Indianapolis, Indiana • Buffalo, New York + 2 more",
      "locations": [
        {
          "city": "Augusta",
          "state": "Georgia"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Buffalo",
          "state": "New York"
        },
        {
          "city": "Charlottesville",
          "state": "Virginia"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06878248"
    },
    {
      "nct_id": "NCT00759642",
      "title": "Lapatinib in Women With Metastatic Breast Cancer Who Have Failed Prior Antihormone Therapy",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Breast Cancer"
      ],
      "interventions": [
        {
          "name": "lapatinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Kansas Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 33,
      "start_date": "2009-03",
      "completion_date": "2018-08-20",
      "has_results": true,
      "last_update_posted_date": "2019-07-01",
      "last_synced_at": "2026-10-15T02:19:02.041Z",
      "location_count": 3,
      "location_summary": "Kansas City, Kansas • Topeka, Kansas • Kansas City, Missouri",
      "locations": [
        {
          "city": "Kansas City",
          "state": "Kansas"
        },
        {
          "city": "Topeka",
          "state": "Kansas"
        },
        {
          "city": "Kansas City",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00759642"
    },
    {
      "nct_id": "NCT03393845",
      "title": "Study of Pembrolizumab Plus Fulvestrant in Hormone Receptor Positive, HER-2 Negative Advanced/Metastatic Breast Cancer Patients",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Fulvestrant",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Nancy Chan, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 47,
      "start_date": "2018-01-29",
      "completion_date": "2027-09-01",
      "has_results": false,
      "last_update_posted_date": "2026-01-02",
      "last_synced_at": "2026-10-15T02:19:02.041Z",
      "location_count": 5,
      "location_summary": "Lansing, Michigan • Omaha, Nebraska • New Brunswick, New Jersey + 2 more",
      "locations": [
        {
          "city": "Lansing",
          "state": "Michigan"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        },
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03393845"
    },
    {
      "nct_id": "NCT03861403",
      "title": "A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumors",
        "Advanced Triple Negative Breast Cancer",
        "Advanced Hormone Receptor Positive/Endocrine Refractory Breast Cancer",
        "Advanced Metastatic Castration-Resistant Prostate Cancer",
        "Advanced Platinum-Resistant Ovarian Cancer"
      ],
      "interventions": [
        {
          "name": "TRX518",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Avelumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Leap Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2019-05-20",
      "completion_date": "2020-07-14",
      "has_results": false,
      "last_update_posted_date": "2023-11-30",
      "last_synced_at": "2026-10-15T02:19:02.041Z",
      "location_count": 4,
      "location_summary": "Lafayette, Indiana • New York, New York • Cleveland, Ohio + 1 more",
      "locations": [
        {
          "city": "Lafayette",
          "state": "Indiana"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Charlottesville",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03861403"
    },
    {
      "nct_id": "NCT00022672",
      "title": "A Study to Evaluate the Efficacy and Safety of Herceptin® (Trastuzumab) in Combination With Arimidex® (Anastrozole) an Aromatase Inhibitor Compared to Arimidex® Alone in Patients With Metastatic Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "trastuzumab (Herceptin®)",
          "type": "DRUG"
        },
        {
          "name": "anastrazole (Arimidex®)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 208,
      "start_date": "2001-01",
      "completion_date": "2009-10",
      "has_results": true,
      "last_update_posted_date": "2013-06-13",
      "last_synced_at": "2026-10-15T02:19:02.041Z",
      "location_count": 20,
      "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 16 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Vallejo",
          "state": "California"
        },
        {
          "city": "Gainsville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00022672"
    },
    {
      "nct_id": "NCT03854903",
      "title": "WI231696: Bosutinib, Palbocicilib and Fulvestrant for HR+HER2- Advanced Breast Cancer Refractory to a CDK4/6 Inhibitor",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Breast Cancer",
        "Human Epidermal Growth Factor 2 Negative Carcinoma of Breast",
        "Hormone Receptor Positive Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Palbociclib",
          "type": "DRUG"
        },
        {
          "name": "Bosutinib",
          "type": "DRUG"
        },
        {
          "name": "Fulvestrant",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Georgetown University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 19,
      "start_date": "2019-04-01",
      "completion_date": "2025-01-09",
      "has_results": false,
      "last_update_posted_date": "2025-02-06",
      "last_synced_at": "2026-10-15T02:19:02.041Z",
      "location_count": 1,
      "location_summary": "Washington D.C., District of Columbia",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03854903"
    },
    {
      "nct_id": "NCT06974604",
      "title": "Preventing Dato-DXd Associated Stomatitis With Dexamethasone Mouthwash, TROPION-DM",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Neoplasms",
        "Lung Neoplasms"
      ],
      "interventions": [
        {
          "name": "Dexamethasone oral",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Brown University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2025-10-22",
      "completion_date": "2029-05-31",
      "has_results": false,
      "last_update_posted_date": "2025-10-24",
      "last_synced_at": "2026-10-15T02:19:02.041Z",
      "location_count": 1,
      "location_summary": "Providence, Rhode Island",
      "locations": [
        {
          "city": "Providence",
          "state": "Rhode Island"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06974604"
    },
    {
      "nct_id": "NCT04699630",
      "title": "A Study of U3-1402 (Patritumab Deruxtecan) in Subjects With Metastatic Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Breast Cancer",
        "Locally Advanced Breast Cancer"
      ],
      "interventions": [
        {
          "name": "U3-1402",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "SCRI Development Innovations, LLC",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 121,
      "start_date": "2021-05-03",
      "completion_date": "2025-04-09",
      "has_results": true,
      "last_update_posted_date": "2026-05-22",
      "last_synced_at": "2026-10-15T02:19:02.041Z",
      "location_count": 11,
      "location_summary": "Birmingham, Alabama • Springdale, Arkansas • Duarte, California + 7 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Springdale",
          "state": "Arkansas"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Fort Myers",
          "state": "Florida"
        },
        {
          "city": "St. Petersburg",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04699630"
    },
    {
      "nct_id": "NCT01870505",
      "title": "BYL719 Plus Letrozole or Exemestane for Patients With Hormone-Receptor Positive Locally-Advanced Unresectable or Metastatic Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic or Locally-advanced Unresectable Breast Cancer"
      ],
      "interventions": [
        {
          "name": "BYL719",
          "type": "DRUG"
        },
        {
          "name": "Letrozole",
          "type": "DRUG"
        },
        {
          "name": "Exemestane",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 52,
      "start_date": "2013-05",
      "completion_date": "2022-02-28",
      "has_results": true,
      "last_update_posted_date": "2024-12-09",
      "last_synced_at": "2026-10-15T02:19:02.041Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01870505"
    }
  ]
}